Specify a stock or a cryptocurrency in the search bar to get a summary
Biophytis
BPTSBiophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France. Address: Sorbonne University, Paris, France, 75005
Analytics
WallStreet Target Price
6 000 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures BPTS
Dividend Analytics BPTS
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History BPTS
Stock Valuation BPTS
Financials BPTS
Results | 2019 | Dynamics |